FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2247114327> ?p ?o ?g. }

• W2247114327 endingPage "e0138054" @default.
• W2247114327 startingPage "e0138054" @default.
• W2247114327 abstract "To determine if sequential treatment with Bevacizumab (Avastin), a monoclonal, VEGF antibody that blocks angiogenesis; Saratin, a 12 kD polypeptide with anti-inflammatory and anti-thrombotic properties; and Ilomastat, a matrix metalloproteinase (MMP) inhibitor, prolongs bleb life following glaucoma filtration surgery (GFS) in a rabbit model. Thirty-two New Zealand White rabbits (eight rabbits per group) underwent GFS in the left eye. Group 1 received a perioperative injection of both Saratin and Bevacizumab, and later, subconjuctival injections of Ilomastat on days 8 and 15. Group 2 received only Saratin perioperatively, and also received Ilomastat injections on days 8 and 15. Group 3, the negative control, received a single perioperative injection of Balanced Saline Solution (BSS) along with post-operative BSS injections on days 8 and 15. Group 4, the positive control, received topical treatment with Mitomycin-C (MMC) at the time of surgery with no further treatment. Blebs were evaluated by an observer masked to treatment every third day. Histology was obtained on two eyes in each group on post-op day twelve as well as all eyes following bleb failure. Eyes in group 1 had a mean bleb survival time of 29 ± 2.7 days, whereas those in group 2 that received the experimental treatment without Bevacizumab had a mean survival time of 25.5 ± 2.7 days. An ANOVA test showed that the Saratin/Ilomastat/Bevacizumab group demonstrated a significant prolongation of bleb survival compared to the BSS control—mean survival time of 19.7 ±2.7 days—(p = 0.0252) and was not significantly different from the MMC positive control group (p = 0.4238)—mean survival time of 32.5 ± 3.3. From tissue histology at day 12, the four different groups showed marked differences in the cellularity and capsule fibrosis. The MMC eyes showed minimal cellularity, were avascular and had minimal fibrous tissue. BSS group showed high cellularity, moderate to high fibrosis, and thicker and more defined capsules than either of the treatment groups and the positive control. Both the Saratin/Ilomastat/Bevacizumab and Saratin/Ilomastat only eyes showed moderate cellularity with minimal fibrosis, with less cellularity and fibrosis present in the triple treatment group. Sequential therapy with multiple agents, including Bevacizumab, prolonged bleb function following GFS in the rabbit model and were significantly better than the negative BSS control. The experimental group did not show the same surface tissue histological thinning and side effects associated with MMC treatment." @default.
• W2247114327 created "2016-06-24" @default.
• W2247114327 creator A5017362034 @default.
• W2247114327 creator A5018051551 @default.
• W2247114327 creator A5020506702 @default.
• W2247114327 creator A5037617891 @default.
• W2247114327 creator A5057222593 @default.
• W2247114327 creator A5060446948 @default.
• W2247114327 creator A5082994754 @default.
• W2247114327 creator A5086511427 @default.
• W2247114327 date "2015-09-22" @default.
• W2247114327 modified "2023-09-26" @default.
• W2247114327 title "Sequential Therapy with Saratin, Bevacizumab and Ilomastat to Prolong Bleb Function following Glaucoma Filtration Surgery in a Rabbit Model" @default.
• W2247114327 cites W123239899 @default.
• W2247114327 cites W1521013991 @default.
• W2247114327 cites W1533495423 @default.
• W2247114327 cites W1585997711 @default.
• W2247114327 cites W1972747417 @default.
• W2247114327 cites W1976253654 @default.
• W2247114327 cites W1976830027 @default.
• W2247114327 cites W1979800217 @default.
• W2247114327 cites W2010392988 @default.
• W2247114327 cites W2016738444 @default.
• W2247114327 cites W2017676546 @default.
• W2247114327 cites W2032622848 @default.
• W2247114327 cites W2035468975 @default.
• W2247114327 cites W2039518489 @default.
• W2247114327 cites W2041430427 @default.
• W2247114327 cites W2045258419 @default.
• W2247114327 cites W2045383913 @default.
• W2247114327 cites W2054821140 @default.
• W2247114327 cites W2059878801 @default.
• W2247114327 cites W2063739951 @default.
• W2247114327 cites W2092660856 @default.
• W2247114327 cites W2408784653 @default.
• W2247114327 cites W2415288713 @default.
• W2247114327 cites W34764880 @default.
• W2247114327 doi "https://doi.org/10.1371/journal.pone.0138054" @default.
• W2247114327 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4578880" @default.
• W2247114327 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26394037" @default.
• W2247114327 hasPublicationYear "2015" @default.
• W2247114327 type Work @default.
• W2247114327 sameAs 2247114327 @default.
• W2247114327 citedByCount "16" @default.
• W2247114327 countsByYear W22471143272016 @default.
• W2247114327 countsByYear W22471143272017 @default.
• W2247114327 countsByYear W22471143272018 @default.
• W2247114327 countsByYear W22471143272019 @default.
• W2247114327 countsByYear W22471143272020 @default.
• W2247114327 countsByYear W22471143272022 @default.
• W2247114327 countsByYear W22471143272023 @default.
• W2247114327 crossrefType "journal-article" @default.
• W2247114327 hasAuthorship W2247114327A5017362034 @default.
• W2247114327 hasAuthorship W2247114327A5018051551 @default.
• W2247114327 hasAuthorship W2247114327A5020506702 @default.
• W2247114327 hasAuthorship W2247114327A5037617891 @default.
• W2247114327 hasAuthorship W2247114327A5057222593 @default.
• W2247114327 hasAuthorship W2247114327A5060446948 @default.
• W2247114327 hasAuthorship W2247114327A5082994754 @default.
• W2247114327 hasAuthorship W2247114327A5086511427 @default.
• W2247114327 hasBestOaLocation W22471143271 @default.
• W2247114327 hasConcept C118487528 @default.
• W2247114327 hasConcept C141071460 @default.
• W2247114327 hasConcept C2776228307 @default.
• W2247114327 hasConcept C2776694085 @default.
• W2247114327 hasConcept C2777802072 @default.
• W2247114327 hasConcept C2777824320 @default.
• W2247114327 hasConcept C2778527774 @default.
• W2247114327 hasConcept C2781092963 @default.
• W2247114327 hasConcept C71924100 @default.
• W2247114327 hasConceptScore W2247114327C118487528 @default.
• W2247114327 hasConceptScore W2247114327C141071460 @default.
• W2247114327 hasConceptScore W2247114327C2776228307 @default.
• W2247114327 hasConceptScore W2247114327C2776694085 @default.
• W2247114327 hasConceptScore W2247114327C2777802072 @default.
• W2247114327 hasConceptScore W2247114327C2777824320 @default.
• W2247114327 hasConceptScore W2247114327C2778527774 @default.
• W2247114327 hasConceptScore W2247114327C2781092963 @default.
• W2247114327 hasConceptScore W2247114327C71924100 @default.
• W2247114327 hasIssue "9" @default.
• W2247114327 hasLocation W22471143271 @default.
• W2247114327 hasLocation W22471143272 @default.
• W2247114327 hasLocation W22471143273 @default.
• W2247114327 hasLocation W22471143274 @default.
• W2247114327 hasOpenAccess W2247114327 @default.
• W2247114327 hasPrimaryLocation W22471143271 @default.
• W2247114327 hasRelatedWork W1583896408 @default.
• W2247114327 hasRelatedWork W1968574077 @default.
• W2247114327 hasRelatedWork W1976405581 @default.
• W2247114327 hasRelatedWork W1988712767 @default.
• W2247114327 hasRelatedWork W2022049485 @default.
• W2247114327 hasRelatedWork W2365084999 @default.
• W2247114327 hasRelatedWork W2385868165 @default.
• W2247114327 hasRelatedWork W2430646269 @default.
• W2247114327 hasRelatedWork W3082983317 @default.
• W2247114327 hasRelatedWork W3195278459 @default.
• W2247114327 hasVolume "10" @default.
• W2247114327 isParatext "false" @default.

• next